Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol
Authors
Tao Gong (ORCID: https://orcid.org/0000-0002-9866-9911)
He Zhao (ORCID: https://orcid.org/0000-0002-3262-9116)
Zhengqiang Yang (ORCID: https://orcid.org/0000-0001-9103-3534)
Wei Sun (ORCID: https://orcid.org/0000-0002-7366-1462)
Yingen Luo
Jingui Li
Ying Li (ORCID: https://orcid.org/0000-0001-9040-5201)
Xiao Li (ORCID: https://orcid.org/0000-0001-9420-9558)
Chinese Academy of Medical Sciences Initiative for Innovative Medicine
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol
Tao Gong, He Zhao, Zhengqiang Yang, Wei Sun et al.
Journal
BMJ Open
Topics
Hepatocellular Carcinoma Treatment and Prognosis
article
Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol
Tao Gong, He Zhao, Zhengqiang Yang, Wei Sun, Yingen Luo, Jingui Li, Ying Li, Xiao Li, Pengfei Tian, Xiaowu Zhang, Peng Song
article en
Abstract
No abstract available for this paper.
Publication Tag
BMJ OpenVol. 14(12)
Institutions
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), First Hospital of China Medical University (CN), China Medical University (CN)
Funders
National Natural Science Foundation of China, Chinese Academy of Medical Sciences Initiative for Innovative Medicine